The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning ...

A study shows reduced-dose apixaban effectively prevents recurrent blood clots in cancer patients, lowering bleeding risks ...